Alnylam Pharmaceuticals (ALNY) Receivables - Other (2018 - 2021)

Alnylam Pharmaceuticals (ALNY) reported Receivables - Other of $500.0 million for Q2 2021, little changed quarter-over-quarter from $500.0 million in Q1 2021.

Alnylam Pharmaceuticals (ALNY) Receivables - Other (2018 - 2021) Analysis & Trends

Alnylam Pharmaceuticals has reported Receivables - Other for 3 years, with the latest figure at $500.0 million in Q2 2021.

  • For the quarter ending Q2 2021, Receivables - Other changed N/A year-over-year to $500.0 million; the trailing twelve-month figure through Jun 2021 stood at $500.0 million (changed N/A YoY), and the FY2020 full-year result was $500.0 million, changed N/A from the prior year.
  • Receivables - Other for Q2 2021 stood at $500.0 million, roughly flat from $500.0 million in the prior quarter.
  • The five-year high for Receivables - Other was $500.0 million in Q3 2020, with the low at $12.5 million in Q4 2018.
  • Historically, Receivables - Other has averaged $402.5 million across 3 years, with a median of $500.0 million in 2020.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn -
7 Psyence Biomedical 212.16 Bn 212.16 Bn -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn
9 Abivax 91.96 Bn 91.96 Bn -
10 Alnylam Pharmaceuticals 37.04 Bn 34.03 Bn 959.66 Mn

Historic Data

Download Data
DateValue
Jun 30, 2021 500.00 Mn
Jun 30, 2021 500.00 Mn
Mar 31, 2021 500.00 Mn
Mar 31, 2021 500.00 Mn
Dec 31, 2020 500.00 Mn
Dec 31, 2020 500.00 Mn
Sep 30, 2020 500.00 Mn
Sep 30, 2020 500.00 Mn
Dec 31, 2018 12.50 Mn
Dec 31, 2018 12.50 Mn